Wells Fargo raised the firm’s price target on Natera (NTRA) to $205 from $190 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $270 from $230 at Barclays
- Natera, Medica Scientia Innovation Research to collaborate on MiRaDoR study
- Natera announces initial translational research data from Phase 3 study
- Natera files to sell 1.95M shares of common stock for holders
- Natera Acquires Foresight Diagnostics for $275 Million